WallStSmart
BHVN

Biohaven Ltd.

NYSE: BHVN · HEALTHCARE · BIOTECHNOLOGY

$9.08
-5.26% today

Updated 2026-06-05

Market cap
$1.72B
P/E ratio
P/S ratio
EPS (TTM)
$-5.57
Dividend yield
52W range
$7 – $19
Volume
2.2M

WallStSmart proprietary scores

23
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
4.0
Quality
C
3.0
Profitability
D
5.0
Valuation
C+
1/9
Piotroski F-Score
Weak
-11.1
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$21.71
+139.10%
12-Month target
Intrinsic (DCF)
Margin of safety
4 Strong Buy10 Buy5 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
Insufficient data
Risks
- Piotroski 1/9 — weak financial health
- Altman Z -11.11 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-149.92M
- Debt/equity 2.16x — high leverage

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-570.28M$-408.17M$-846.42M$-738.82M$-130.53M
EPS$-5.57
Free cash flow$-338.76M$-334.77M$-586.50M$-610.15M$-149.92M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
BHVN$1.72B234.33.05.04.0Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Biohaven Ltd. trades at $9.08. Our Smart Value Score of 23/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -11.11, it sits in the distress.

Frequently asked questions

What is Biohaven Ltd.'s stock price?

Biohaven Ltd. (BHVN) trades at $9.08.

Is Biohaven Ltd. overvalued?

Biohaven Ltd. carries a Smart Value Score of 23/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Biohaven Ltd. (BHVN)?

The 12-month analyst consensus target is $21.71, about 139.1% above the current $9.08. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Biohaven Ltd.'s Altman Z-Score is -11.11, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNYSE
CurrencyUSD

Quick metrics

P/S ratio
ROE-500.14%
Beta3.31
50D MA$9.58
200D MA$11.81
Shares out0.15B
Float0.12B
Short ratio
Avg volume2.2M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years